Ventuno Biotech

Based in Lyon, France, Ventuno Biotech specializes in developing innovative immuno-oncology therapies that harness the immune system to combat cancer, particularly targeting challenging tumor types. Ventuno Biotech, founded in 2025 in Lyon, France, focuses on cancer immunotherapies. The company has successfully completed 2 deals, with its most recent funding round occurring on November 27, 2025. They raised EUR 2 million in Seed funding led by OCTALFA, with participation from Turenne Groupe.

The founder's history is not specified, nor are there mentions of subsidiaries or parent companies. Ventuno Biotech is focused on developing innovative cancer therapies that leverage the immune system's capabilities to target and eliminate cancer cells, particularly in difficult-to-treat tumors. Their core offerings are centered around next-generation cancer immunotherapies that aim to enhance the body’s immune response against cancer. The company's products are designed for healthcare providers, including hospitals and oncology clinics, and serve patients diagnosed with various forms of cancer.

Ventuno Biotech’s therapeutic solutions are marketed primarily in Europe and are tailored for regions where there is a significant need for advanced cancer treatment options. The release of these therapies is aimed at addressing the urgent demand for more effective cancer care, demonstrating the company's commitment to advancing patient outcomes. Ventuno Biotech generates revenue through a structure that includes partnerships with healthcare institutions and direct sales of their immunotherapy products. The company is engaged in B2B transactions, primarily targeting hospitals and oncology centers that incorporate these advanced treatments into their patient care protocols.

Revenue streams are bolstered by collaboration agreements and potential licensing of their proprietary technologies to larger pharmaceutical companies. Pricing plans for the products are structured around specific treatment regimens, and the company establishes agreements that ensure consistent supply and access for its therapeutic offerings. Ventuno Biotech's flagship products are positioned to provide significant value in the oncology market, catering to patients with challenging cancer diagnoses. In November 2025, Ventuno Biotech raised EUR 2 million in Seed funding, which will be utilized to reinforce discovery and translational research programs and build preclinical data for its lead immuno-oncology assets.

The company is focused on designing and launching new products that enhance its cancer treatment portfolio. Plans for expanding into new markets include targeting additional regions across Europe by the end of 2026, aligning with their goal to address the urgent needs of cancer patients globally.